Sulbactam

Generic Name: Sulbactam

Brand Names: Unasyn, Xacduro

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁NO_₅S

CAS Number: 68373-14-8

Unique Ingredient Identifier: S4TF6I2330

Background: Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.

Indication: Sulbactam is currently available in combination products with ampicillin. Within this formulation it is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.

Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, Klebsiella spp. (including K. pneumoniae), Proteus mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus.

Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae), Bacteroides spp. (including B. fragilis), and Enterobacter spp.

Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).

Associated Conditions: Animal bite, Bacterial Infections, Bacterial Infections caused by Beta lactamase producing bacteria, Bacterial Sinusitis, Bites, Human, Catheter Related Infections, Community Acquired Pneumonia (CAP), Gynecological Infection, Infective Endocarditis (IE), Intraabdominal Infections, Nosocomial Pneumonia, Postoperative Infections, Postoperative Wound Infection, Skin and Subcutaneous Tissue Bacterial Infections, Complicated Bacterial Infections caused by Beta lactamase producing bacteria, Moderate Bacterial Infections, Severe Bacterial Infections

Associated Therapies: -

Clinical Trials

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its ...

Everest Medicines presented eravacycline data at IDWeek 2024, showing broad antimicrobial activity against Carbapenem-resistant Acinetobacter baumannii and consistent efficacy against Gram-positive and Gram-negative bacteria. Eravacycline, a fluorocycline, is approved for complicated intra-abdominal infections and has shown high treatment effectiveness.

morningstar.com

a month ago

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

Zai Lab reports Q3 2024 net product revenue growth of 47% y-o-y to $101.8M, positive China bridging study results for KarXT in schizophrenia, and global Phase 1 data suggesting best-in-class potential for ZL-1310 in extensive-stage SCLC. The company expects three product launches in China by end of 2024 and up to four NMPA regulatory submissions in the next six months. Cash position was $716.1M as of September 30, 2024.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy